Pages that link to "Q42670886"

The following pages link to Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa (Q42670886):

Displaying 44 items.

• The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? (Q27021472) (← links)
• Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy (Q31052050) (← links)
• Pompe disease: literature review and case series (Q35029971) (← links)
• Lung MRI and impairment of diaphragmatic function in Pompe disease (Q35595602) (← links)
• Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function. (Q36154874) (← links)
• Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up (Q36582225) (← links)
• Diaphragm Pacing as a Rehabilitative Tool for Patients With Pompe Disease Who Are Ventilator-Dependent: Case Series (Q36875150) (← links)
• Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients (Q37394520) (← links)
• The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients (Q37479842) (← links)
• Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature (Q37704865) (← links)
• Exercise in muscle glycogen storage diseases (Q38261159) (← links)
• Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel (Q38800985) (← links)
• Treatment of muscle weakness in neuromuscular disorders (Q38845507) (← links)
• Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. (Q38884347) (← links)
• European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. (Q39287288) (← links)
• A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease (Q40499037) (← links)
• Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment (Q41448556) (← links)
• Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD). (Q42787786) (← links)
• Quantitative assessment of lingual strength in late-onset Pompe disease (Q43493160) (← links)
• Enzyme replacement in neuronal storage disorders in the pediatric population (Q43948150) (← links)
• Should patients with asymptomatic pompe disease be treated? A nationwide study in France (Q44725647) (← links)
• Treatment Opportunities in Patients With Metabolic Myopathies (Q45872248) (← links)
• Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study (Q46933420) (← links)
• Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy (Q47190390) (← links)
• Screening for late-onset Pompe disease in western Denmark. (Q47290108) (← links)
• Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease. (Q47852062) (← links)
• Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. (Q48179948) (← links)
• Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. (Q51718537) (← links)
• Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. (Q52647391) (← links)
• Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up. (Q54310178) (← links)
• Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients. (Q55047221) (← links)
• Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease—a long-term follow-up (Q57705436) (← links)
• Screening for late-onset Pompe disease in undiagnosed myopathies (Q58036044) (← links)
• Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study (Q64050938) (← links)
• Improved efficacy of a next-generation ERT in murine Pompe disease (Q64122273) (← links)
• Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study (Q90322484) (← links)
• Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease (Q90347187) (← links)
• Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease (Q90753095) (← links)
• Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease (Q91991427) (← links)
• Challenges in treating Pompe disease: an industry perspective (Q92487836) (← links)
• Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis (Q92672695) (← links)
• The role of rehabilitation in the management of late-onset Pompe disease: a narrative review of the level of evidence (Q92834631) (← links)
• Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase (Q96292693) (← links)
• Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study (Q98944076) (← links)